Edition:
United Kingdom

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

6.90USD
9:00pm BST
Change (% chg)

$-0.10 (-1.43%)
Prev Close
$7.00
Open
$6.98
Day's High
$7.06
Day's Low
$6.75
Volume
262,602
Avg. Vol
541,604
52-wk High
$15.95
52-wk Low
$3.41

Latest Key Developments (Source: Significant Developments)

Tg Therapeutics Provides Business Update And Reports First Quarter 2019 Financial Results
Friday, 10 May 2019 

May 10 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES WERE $92.5 MILLION AS OF MARCH 31, 2019.QTRLY LOSS PER SHARE $0.43.TG THERAPEUTICS-BELIEVES CASH, CASH EQUIVALENTS & INVESTMENT SECURITIES ON HAND AS OF MARCH 31 SUFFICIENT TO FUND PLANNED OPERATIONS THROUGH MID-2020.Q1 EARNINGS PER SHARE VIEW $-0.44 -- REFINITIV IBES DATA.  Full Article

TG Therapeutics Announces Long-Term Follow-Up Data From The Phase 2 Trial Of Ublituximab In Patients With Multiple Sclerosis
Tuesday, 7 May 2019 

May 7 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS ANNOUNCES LONG-TERM FOLLOW-UP DATA FROM THE PHASE 2 TRIAL OF UBLITUXIMAB IN PATIENTS WITH MULTIPLE SCLEROSIS AT THE AMERICAN ACADEMY OF NEUROLOGY 71ST ANNUAL MEETING.TG THERAPEUTICS INC - UBLITUXIMAB CONTINUES TO BE WELL TOLERATED, WITH A MEDIAN DURATION OF FOLLOW-UP OF 97.5 WEEKS.TG THERAPEUTICS INC - NO SUBJECTS DISCONTINUED DUE TO AN ADVERSE EVENT (AE) RELATED TO UBLITUXIMAB ON PHASE 2 OR DURING OLE.  Full Article

TG Therapeutics Announces About $85 Mln In Equity And Debt Financings
Friday, 1 Mar 2019 

March 1 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS ANNOUNCES APPROXIMATELY $85 MILLION IN EQUITY AND DEBT FINANCINGS.TG THERAPEUTICS INC - COMPANY PRICED A PUBLIC OFFERING OF ITS COMMON STOCK FOR GROSS PROCEEDS OF APPROXIMATELY $25.2 MILLION.TG THERAPEUTICS INC - COMPANY ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF UBLITUXIMAB AND UMBRALISIB.  Full Article

TG Therapeutics Qtrly Loss Per Share $0.43
Friday, 9 Nov 2018 

Nov 9 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.TG THERAPEUTICS INC QTRLY LOSS PER SHARE $0.43.TG THERAPEUTICS - BELIEVES CASH, CASH EQUIVALENTS ON HAND AS OF SEPT 30, WILL BE SUFFICIENT TO FUND CO'S PLANNED OPERATIONS THROUGH END OF 2019.  Full Article

TG Therapeutics Inc QTRLY Loss Per Share $0.59
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.TG THERAPEUTICS INC QTRLY LOSS PER SHARE $0.59.TG THERAPEUTICS - CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, AND INTEREST RECEIVABLE WERE $126.3 MILLION AS OF JUNE 30, 2018.TG THERAPEUTICS - CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, INTEREST RECEIVABLE ON HAND AT QUARTER END ENOUGH TO FUND PLANNED OPERATIONS INTO H2 2019.  Full Article

TG Therapeutics Reports Qtrly Loss Per Share Of $0.59
Tuesday, 8 May 2018 

May 8 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, AND INTEREST RECEIVABLE WERE $109.2 MILLION AS OF MARCH 31, 2018.QTRLY LOSS PER SHARE $0.59.Q1 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.TG THERAPEUTICS-CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, INTEREST RECEIVABLE ON HAND AS OF MARCH 31, SUFFICIENT TO FUND OPERATIONS THROUGH MID-2019.  Full Article

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

TG Therapeutics Announces Initiation Of Randomized Phase II Trial In Follicular Lymphoma
Monday, 27 Nov 2017 

Nov 27 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS ANNOUNCES INITIATION OF NATIONAL CANCER INSTITUTE/SWOG-SPONSORED RANDOMIZED PHASE II TRIAL IN FOLLICULAR LYMPHOMA.  Full Article

TG Therapeutics qtrly net loss per common share $0.48
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - TG Therapeutics Inc ::TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results.TG therapeutics inc - qtrly net loss per common share $0.48.Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.TG therapeutics inc - believes cash and cash equivalents will be sufficient to fund planned operations through 2018​.  Full Article

TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial
Monday, 16 Oct 2017 

Oct 16 (Reuters) - TG Therapeutics Inc : :TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial.TG Therapeutics Inc - ‍targeting an NDA/BLA filing for combination of TGR-1202 + TG-1101 in 2H18​.TG Therapeutics Inc - ‍top-line ORR data from UNITY-CLL trial expected in 2Q18​.  Full Article